In 2022, the Global Mucopolysaccharidosis (MPS) Treatment Industry is poised for substantial growth, with an estimated worth of US$2.38 billion. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 5.9% from 2022 to 2029, culminating in a market valuation of US$ 3.37 billion by the end of the forecast period. This surge is attributed …